Research
Cellular
Body mass index (BMI) is a risk factor for the development of oesophageal adenocarcinoma, colorectal, hepatocellular, gallbladder, and pancreatic cancers.
Practitioners should consider BMI as a significant factor in assessing cancer risk in patients with excess adiposity.
StrongSupportsmedium confidence
A large volume of evidence demonstrates that body mass index (BMI), as an approximation for general adiposity, is a risk factor for the development of oesophageal adenocarcinoma, and colorectal, hepatocellular, gallbladder and pancreatic cancers.
Why this rating
The claim is supported by a large volume of evidence, indicating a strong basis for the association.
Source
Excess adiposity and gastrointestinal cancer
P Coe et al. · British journal of surgery · 2014
DOI 10.1002/bjs.9623
Meta-analysisCited 39×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Indices of increased central adiposity, such as waist circumference, are associated with increased risk of oesophageal adenocarcinoma and colorectal cancer.Strong
- There are few data that convincingly demonstrate significant reductions in risk of gastrointestinal cancers following weight-reducing strategies.Strong
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →